Table 2 The changes in the clinical process and composite outcomes of patients before and after COVID-19 pandemic
From: Management strategies and outcomes of acute coronary syndrome (ACS) during Covid-19 pandemic
Variables | COVID-19 group (n = 171) | pre-COVID-19 group (n = 52) | p |
|---|---|---|---|
Peak hscTn-I, ng/L | 63,374.6 ± 12,261.8 | 111,995.2 ± 2467.3 | 0.18 |
Peak of BNP, pg/ml | 648.5 ± 294.2 | 605.5 ± 6815.1 | 0.91 |
HSP90a, ng/ml | 104.2 ± 71.8 | 156.5 ± 106.3 | 0.004* |
Echocardiography | |||
Proportion of abnormal segment, % | 111 (64.9) | 33 (63.5) | 0.84 |
LVEF, % | 54.3 ± 11.1 | 53.8 ± 11.4 | 0.75 |
Composite outcomes, n (%) | 20 (11.6) | 7 (13.5) | 0.55 |
In-hospital death, n (%) | 1 (0.6) | 2 (3.8) | Â |
Cardiogenic shock, n (%) | 7 (4.1) | 2 (3.8) | Â |
Sustained VT/VF, n (%) | 2 (1.2) | 1 (1.9) | Â |
Use of MCS, n (%) | 14 (8.2) | 3 (5.8) | Â |